Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $5.90 USD
Change Today -0.04 / -0.67%
Volume 2.2M
ARRY On Other Exchanges
As of 8:10 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

array biopharma inc (ARRY) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/5/15 - $8.59
52 Week Low
10/13/14 - $2.98
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ARRAY BIOPHARMA INC (ARRY)

array biopharma inc (ARRY) Related Bloomberg News

View More Bloomberg News

array biopharma inc (ARRY) Related Businessweek News

No Related Businessweek News Found

array biopharma inc (ARRY) Details

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company’s drugs in Phase III clinical trials include Binimetinib and Encorafenib for the treatment of cancer. Its drug candidates in Phase II clinical trials include Filanesib, a kinesin spindle protein inhibitor for multiple myeloma; ARRY-797, a p38 inhibitor for Lamin A/C-related dilated cardiomyopathy; ASC08/Danoprevir, a protease inhibitor for Hepatitis C virus; ASLAN001/ARRY-543, a pan-HER inhibitor for gastric or breast cancer; Ipatasertib/GDC-0068, an AKT inhibitor for cancer; Motolimod/VTX-2337, a toll-like receptor for cancer; and LY2606368, a chk-1 inhibitor for cancer. The company’s Phase Ib drug candidate comprises GDC-0575, a chk-1 inhibitor for cancer; and ONT-380/ARRY-380, a HER2 inhibitor for breast cancer, as well as Phase I drug candidate includes GDC-0994, an ERK inhibitor for cancer and LOXO-101, a PanTrk inhibitor for cancer. Array BioPharma Inc. has collaboration agreements with Biogen Idec MA Inc.; Array and Celgene Corporation and Celgene Alpine Investment Co., LLC; Genentech, Inc.; Loxo Oncology, Inc.; Novartis International Pharmaceutical Ltd.; and Oncothyreon Inc. The company was founded in 1998 and is headquartered in Boulder, Colorado.

156 Employees
Last Reported Date: 08/21/15
Founded in 1998

array biopharma inc (ARRY) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $548.8K
Chief Operating Officer
Total Annual Compensation: $343.8K
Compensation as of Fiscal Year 2014.

array biopharma inc (ARRY) Key Developments

Array BioPharma Seeks Acquisitions

Array BioPharma Inc. (NasdaqGM:ARRY) is seeking acquisitions. Array BioPharma will use a portion of the net proceeds from the offering to repay or refinance existing indebtedness or other corporate borrowings, or to acquire or invest in complementary businesses, technologies, drugs, drug candidates or other intellectual property.

Array BioPharma Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2015

Array BioPharma Inc. reported unaudited earnings results for the fourth quarter and full year ended June 30, 2015. For the quarter, the company reported total revenue of $12,320,000 compared to $6,011,000 a year ago. Loss from operations was $20,003,000 compared to $25,783,000 a year ago. Net loss was $12,734,000 or $0.09 per basic and diluted share compared to $28,237,000 or $0.22 per basic and diluted share a year ago. The $6.3 million increase in revenue from the prior period was primarily due to $5.7 million in reimbursable research and development expenses from Novartis. For the year, the company reported total revenue of $51,909,000 compared to $42,078,000 a year ago. Income from operations was $3,293,000 compared to loss from operations of $75,618,000 a year ago. Net income was $9,369,000 or $0.07 per basic and diluted share compared to net loss of $85,257,000 or $0.69 per basic and diluted share a year ago.

Array BioPharma Inc. to Report Q4, 2015 Results on Aug 03, 2015

Array BioPharma Inc. announced that they will report Q4, 2015 results at 11:00 AM, GMT Standard Time on Aug 03, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARRY:US $5.90 USD 0.00

ARRY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arena Pharmaceuticals Inc $2.71 USD 0.00
CTI BioPharma Corp $1.58 USD -0.02
Evotec AG €3.67 EUR -0.087
Exelixis Inc $5.95 USD -0.10
Progenics Pharmaceuticals Inc $7.33 USD -0.34
View Industry Companies

Industry Analysis


Industry Average

Valuation ARRY Industry Range
Price/Earnings 89.8x
Price/Sales 16.2x
Price/Book 19.8x
Price/Cash Flow 90.1x
TEV/Sales 10.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARRAY BIOPHARMA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at